Key result
COVID-19 linked to acute Type IV MI from early stent thrombosis in a single patient.
Why the study?
COVID-19 infection is partly mediated by hypercoagulability leading to thrombotic angiopathy, acute myocardial injury, and pulmonary thromboembolic disease.
Case Report (n=1)
Highlights the risk of early acute stent thrombosis and Type IV myocardial infarction in patients with COVID-19, likely mediated by infection-induced hypercoagulability.
Answers are grounded in this paper and cite their sources.
Raises possibility of COVID-19 precipitating early stent thrombosis; single case leaves causal link unproven.
New facts suggest that COVID-19 coronavirus infection is partly mediated by hypercoagulability reactions characterized by micro- and macrovascular thrombotic angiopathy, which leads to acute myocardial injury, myocarditis, arrhythmias and numerous cases of pulmonary thromboembolic disease . The article presents a clinical observation of acute myocardial infarction development as a result of early thrombosis of an implanted coronary stent in a patient diagnosed with a new coronavirus infection COVID-19.
No takes yet. Share an insight, caveat, or question.
Ardashev et al. (2021) conducted a case report in COVID-19 and Type IV myocardial infarction (n=1). COVID-19 infection was evaluated on Development of acute myocardial infarction (Type IV) due to early stent thrombosis. COVID-19 infection was associated with the development of acute Type IV myocardial infarction due to early thrombosis of an implanted coronary stent in a single patient.
Synapse has enriched 10 related papers. Consider them for comparative context: